Kasugai

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Chronic kidney disease2 trials
• IgA nephropathy2 trials
• Childhood cancers1 trial
• Chronic myeloid leukaemia1 trial
• Coronary artery disease1 trial
• Heart failure1 trial
• High blood pressure1 trial

Phase

• Phase 32 trials
• Phase 21 trial

Status

• Completed3 trials
• Active, not recruiting1 trial
• Recruiting1 trial

Lead sponsor

• Novartis Pharmaceuticals5 trials

Running trials

• Recruiting

  Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP

  NCT07830719· Phase 2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

  NCT04557462· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Heart failure1 recruiting

Closed trials

• Completed

  Special Drug Use Surveillance of Entresto Tablets (Hypertension)

  NCT05976230· Novartis Pharmaceuticals· Source

• Completed

  Special Drug Use-results Surveillance of Scemblix Tablets

  NCT05421091· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

  NCT04578834· Phase 3· Novartis Pharmaceuticals· Source